According to a filing submitted to the U.S. Securities and Exchange Commission, biopharmaceutical company Telomir Pharmaceuticals has officially appointed Andriy Mushak as its part-time Chief Financial Officer, with the appointment scheduled to take effect on June 6, 2026.

According to a filing submitted to the U.S. Securities and Exchange Commission, biopharmaceutical company Telomir Pharmaceuticals has officially appointed Andriy Mushak as its part-time Chief Financial Officer, with the appointment scheduled to take effect on June 6, 2026.

老虎证券2026/06/08 21:09

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This appointment marks a critical step for the company in strengthening its financial management team. Mr. Mushak will leverage his extensive professional financial experience to support the company's strategic development. The company aims to optimize its financial structure to better adapt to future business expansion and R&D needs. Market observers will closely monitor the potential impact of this executive change on the company's operations and long-term financial performance.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to a filing submitted to the U.S. Securities and Exchange Commission, biopharmaceutical company Telomir Pharmaceuticals has officially appointed Andriy Mushak as its part-time Chief Financial Officer, with the appointment scheduled to take effect on June 6, 2026.

You may also like

Crypto prices